Chemed Corporation (CHE) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Chemed Corporation published the results on October 27, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Chemed Corporation reports EPS two ways: GAAP, under the accounting rules every US filer follows, and Adjusted Diluted EPS, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Chemed reports its figures in thousands; this page shows them in millions. The revenue line is what Chemed calls service revenues and sales.

Source: Chemed Q3 2026 results, October 27, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Chemed Corporation splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Chemed Corporation's VITAS revenue was $457 million in Q3 2026, up 12% from $408 million in Q3 2025, 66% of total revenue.
• Chemed Corporation's Roto-Rooter revenue was $234 million in Q3 2026, up 8% from $217 million in Q3 2025, 34% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Chemed Corporation said:

“Based on the Company's financial results through September 30, 2026, we estimate that we will be at or slightly above the high-end of our full-year 2026 adjusted EPS guidance issued in conjunction with our press release, dated July 28, 2026, discussing our second quarter 2026 earnings.”

Source: Chemed Q3 2026 release, Oct 27, 2026.

This is the company's own guidance as of Oct 27, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the CHE forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Service revenues and sales in millions and GAAP diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for Chemed Corporation's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 27, 2026

Chemed runs two unrelated businesses: VITAS, a hospice provider, and Roto-Rooter, a plumbing and drain cleaning company. In Q3 2026 VITAS brought in $457.4 million of Chemed's $690.9 million in revenue and Roto-Rooter $233.5 million. Total revenue rose 10.6%. (Chemed Q3 2026 release, Oct 27, 2026)

VITAS net revenue rose 12.2%. Chemed attributes this mainly to a 9.4% increase in days of care and a geographically weighted Medicare reimbursement rate increase of about 2.2%. Average daily census was 24,428 patients and admissions were 18,995, up 7.2%. Routine home care is most of the business: homecare revenue was $406.0 million, 86.4% of VITAS revenue before the Medicare cap allowance. (Chemed Q3 2026 release, Oct 27, 2026)

VITAS depends on one payer. Over 90% of its revenue comes from the U.S. government through Medicare, and Medicare caps what each hospice program can be paid. VITAS accrued $828,000 of Medicare Cap billing limitation in Q3 2026, against $6.1 million a year earlier; five of its 33 Medicare provider numbers carry a billing limitation totaling $6.1 million. (Chemed Form 10-K, 2025, Feb 27, 2026; Chemed Q3 2026 release, Oct 27, 2026)

Roto-Rooter revenue rose 7.5%. Branch residential revenue was $158.8 million, up 5.2%, branch commercial revenue $59.9 million, up 9.0%, and revenue from independent contractors $16.9 million, flat. In the quarter Roto-Rooter re-acquired franchise territories in California for about $62.5 million, covering a population of over 12 million people. (Chemed Q3 2026 release, Oct 27, 2026)

Chemed's GAAP diluted EPS was $5.45 in Q3 2026 and its Adjusted Diluted EPS $6.75. The adjusted figure adds back $20.2 million of pre-tax items: legal settlements ($7.0 million), stock option expense ($6.0 million), long-term incentive compensation ($3.2 million), amortization of reacquired franchise rights ($2.4 million) and acquisition expense ($1.7 million). After tax, those items cost $17.1 million. (Chemed Q3 2026 release, Oct 27, 2026)

Buybacks cut Chemed's diluted share count to 13,135 thousand from 14,409 thousand a year earlier. Chemed repurchased 125,000 shares for $66.0 million in the quarter, at $528.24 a share, and 1,235,000 shares over the trailing 12 months at an average of $427.62. About $73.7 million of authorization remained at September 30, 2026. (Chemed Q3 2026 release, Oct 27, 2026)

Chemed had $236.0 million of long-term debt at September 30, 2026, against none a year earlier, which its 10-Q attributes primarily to acquisitions and stock repurchases. Interest expense rose to $2.1 million from $457 thousand. The effective tax rate was 25.9%, against 23.1%. (Chemed Q3 2026 release, Oct 27, 2026; Chemed Form 10-Q, Q3 2026, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Chemed did not publish new guidance figures in its Q3 2026 release. It said it expects full-year 2026 adjusted EPS to be at or slightly above the high end of the guidance it issued with its Q2 2026 release on July 28, 2026, and that further detail would be given on the conference call. (Chemed Q3 2026 release, Oct 27, 2026)

A consensus figure is the average of the models published by the analysts who cover Chemed Corporation, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Chemed Corporation's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning CHE is on is CHE a buy or a sell?, what analysts expect next is on the CHE forecast, and what the company does is on the Chemed Corporation (CHE) stock page.

Every number on this page can be traced to a document Chemed Corporation published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.